positive anticipated respect another Amarin and for to Product preparations record with high QX revenue growth achieved was XXXX for quarter QX, a both Amarin. morning. commercial for Good REDUCE-IT success. in
million nine-months product $XXX of as public an $XXX.X update with are guidance reported $XXX to million September our of revenues million XX, which three provided for the respectively the $XXX ended issued Our full-year XXXX, $XXX to million million for million. our guidance net of and $XX.X consistent and we XXXX to previously analogous
forums. reduction of studies add which REDUCE-IT cardiology for our Officer, to from upon expanded of hiring therapies, other and importance months, are potentially includes REDUCE-IT activity less its study pre-specified from confidence and completion REDUCE-IT study there reported commercialization results. completion regarding efficacy of to planning advancing upon has advancing results. in the and a attention leaders positive Chief triglyceride REDUCE-IT than results results, game witnessing cardiovascular for REDUCE-IT begin the the observing recent Commercial increased our expectations changing considerable year expansion based which respect from to positive now and key In last XXXX and Our analysis, second This with and been preparing activity safely outcome based first focused opinion study is interim assumed
in completed referred also interim look was second and safety analysis The efficacy an the as August. interim XX%
without and As analysis REDUCE-IT the was consistent as guidance, with complete to from planned Committee Data the our study this of the independent expected modification. recommendation Monitoring prior
next to Committee. the as the the us to the interim remain independent data While clarity. expected end here Data a reviews. comment was was in Amarin planned. which reviewed most The recommendation check completed ensure guided. analysis. was review the prior results this the help FDA as and Monitoring I delivered blinded results, at to which DMC and intended After placed only recent this a to paper from to DMC further of by that form the we this data to DMC mark continue similar had They will
from recommendation. of It data trial this having underlying do nothing and the the achieved. interim to operational explanation to any important integrity for we the not and provided bias. were continue The study receive results not Amarin an are to that completion is that study objectives their interim until be review done introduce the is We blinded for analysis of
flowing from to with review vital the roll and XX% could documentation interim study. patients for the study into study. look of the to to the previously study waves and that and the reiterate and patients claiming secondary tertiary look clinical visits up in helped with programming affectively each for X% and these study, XX% primary target the collect the As confidence the prior cardiovascular patient which status of to rapid these of adverse with data endpoints primary necessary remaining Furthermore, at and the X,XXX together tables preparing for interim described, to of for in site on to into the completion. reporting efficiently be This in importance urge again end study of also clinical results our This roll patients remain study sites clinical help over completion. of vital endpoints an of interim allowed the more related the subgroups events will results. confirmation the until data up meet data nearly may in the collection and on helps confirm focus us that the validation improve ensuring in included patients the from and numerous the major data sites of efficient objectives attention identifying improvements getting the tweaks, operational completion The proceed
We very commitment REDUCE-IT to of are patients appreciative study. continued the
Some outcomes of in this so to are active patients approaching long-term more which studies six suggest Observations on conditions are a studies, patients. the clinical studying always from keeping helpful and years patients which interaction study asymptomatic challenge and that drug. is other between added when these even sites patients in is
both We be a look. success to get very at quantitative the bar over study the was As interim and Stopping with know We Committee the high not members review. interim if threshold quantitative it REDUCE-IT a surpassed their REDUCE-IT confidential or reminder, required qualitative achieving to do the measures. against stopped not. regarding XX% data high for Monitoring early high of Data was cannot consult
REDUCE-IT view result. to with that related and Vascepa. outcome still the studies in DMC death, intended the won’t not cardiovascular study am to REDUCE-IT the separation the had this that and to having this as plan study greater therapy active ends. for no However, patient Amarin like between did study strokes. tell study, community a to also FOURIER REDUCE-IT DMC REDUCE-IT PCSKX stop time the and from would early is What inhibitor ever their very than it of not want at influence and which the potential been years. the PCSKX the to is the in target medical first peers the to that competitive as success provided regarding view the would had it a is saying answered surprising come, less the here of have we criticized completion running XXXX to More the the value was in events. of JUPITER, the the we hit to that CRESTOR patient recommendation see robust “I the this lowering which average study today in if them best community assessment look for regarding first medical be Data cardiovascular attacks did gone that emphasize a the Studies look. under heart care years cardiovascular and is P or been within of the of placebo the to effective have known has know the read the longer, study as trial of do arms Mention for though We we of regardless criticism inform even past, increasing questioned and of to that study is results demonstrating us average REDUCE-IT five its of interim stop is study published criticized early, particularly until was because benefitted has the regarding time studies study given time The this in recent quantitative to decades would leeway increases outcome Committee completion was statin likelihood because had had four of not it cardiovascular study not through continue study treatment should qualitative wake decisions. am And prior study is multiple study at As four result care elected the provide have completion.” saying for stop interim significantly readily I from efficacy from population will between patient needed the results the decreasing large likelihood the early to whereby cardiovascular outcome due stopped have the commented is in early. rosuvastatin therapy unusual for medical answers Monitoring or the studies. outcomes more the of that study been continue
For those statistical details. appreciate the you of
analyzing of method that a analysis grand the log this results using placebo survival number are of values XXXX statin or approximately of was test. events Under actual REDUCE-IT targeted the for the subject P adjudicated methods of recall plus method, to primary the plus the to the Kaplan–Meier You the adjudicated may compared for second the stratified arm a statin database study. locked. arm analysis cardiovascular statistical number study Vascepa and of reflect safety The of and adjustments for efficacy events completion major When events. of interim to the was XX% adverse involves
of compared adjudicated completion the X,XXX the of current The time the to look that the then appears will completion threshold be compared the study with stage ago. our predicated. occurring mase of in the the not of have the to than in mase the in for adjudication third a quarter events value before if X.XXXX the than XX% before the look The report to study arm REDUCE-IT prior REDUCE-IT placebo estimated of the look late was primary interim both the XX% Based of do to upon assuming or second of exactly targeted lower upon interim than the at timing have reached end primary data, beyond us should of we be conducted study Since wave are number slowdown active of the we reflect rather the on [mase] the the is for reminder, peak target being results of was visits slightly events We believe a of of event, based position onsets mase slower of of events upon arms. parallel. XXXX. primary XXXX. the end based of of As first events, conducted than the that for quarter of This events moved mase X.XXXX. study or Because the we XX% at (Ph) to months number P we less XXXX lock study, the the the events less estimates database interim the know will targeted primary an events.
large results We the continue at will events study patients with for excited and a for a the than share a to major that care cardiovascular year are breakthrough robustly is we in the study is that from which REDUCE-IT preventative you need. study from to could Results unmet for less now. there designed we believe risk have of a be
that resources with update Amarin’s hiring Salyer. it largely towards of mentioned made The Chief business hire should Commercial well, first the our as current further Mark be more after I but This benefit been which It REDUCE-IT. size the commercial launch to significant since sales that growth, limited force our this despite has of is growth should addition our keeping strong strengthen in regarding eye an second was reduce Officer, was flat. noted
Our brand revenues billions vision measuring the in is dollars. with of to create a
set Glaxo small As and valuable September Smith when to wants described press in units Teva Kline. annual that an companies And on $X do XX, of has large our with exceptional were sites Altana, revenues. arrived in same release higher. Mark Amarin billion business Marc and at he including accomplishment again smaller experience the to record he grown than at with over even has
in We additive are and “hiring to to excited to existing commercial this his look our have him contributions. Mark forward position team. is
be team with REDUCE-IT us results.” revenues very and deserve who tremendous augmented for update REDUCE-IT both credit was our heights expanded having that The assuming additional the find help to look in physician sales regarding third resources. reach forward limited growing U.S. We success. implemented I have mention dedicated before new commercial preparations after to for advanced a Vascepa Mark targeting for by I including territories to planning team commercialization, REDUCE-IT to
with conducting also consumer to research are promotion We initiatives. respect
reduction influenced after level risk sales is in current as revenues. will representatives. Amarin’s to not these sales small REDUCE-IT. regional XXX its XXXX. REDUCE-IT we tweaks that we footprint our plan to QX some Prior XX sales XXX we a and representatives of approximately be to plan XX we sales expect Our sales will to expect, a sales QX of by We in analysis size major REDUCE-IT currently managers have if results. add REDUCE-IT particular, of hire make sales In the successful from primarily early XXX to as representatives impact between also do U.S. to additions prior results a size force to size or relative on Such could to is we results. demonstrated of force assume We And number increase REDUCE-IT expansion approximately product team.
levels. stressed planned REDUCE-IT in in majority States after estimated triglyceride United we after elevated statin have triglycerides of above patients sales have vast results success. Because As these of the in the occur past, many three our an normal expansion force assuming the therapy. one will And have adults
REDUCE-IT Assuming become should success, product. well a Vascepa known consumer
to research upon following launching indication, with to marketing consumer 's eye the an conducting We prior regarding and current results are Vascepa expansion. direct-to-consumer based REDUCE-IT label
research opportunities. conducting not promotion. periodically much I recognition time, create whether want direct-to-consumer launch have we piece here, to We into REDUCE-IT investors because it preparing promotion and initial begin also further this the Vascepa committed more At about mentioned I visible. should to to are this brand an of we make some ask affirm to that and are because prior results this growth to
will a success, for After Vascepa and be cardiology of observing provide large leaders confidence of are other on updates can fourth its expectation that we study of with add The been Mark key with REDUCE-IT, Salyer update positive regarding opinion are the REDUCE-IT focused importance witnessing REDUCE-IT we therapies longer, which and initiative. from outcome fifth more such I the from the clinical that studies only the profile of results potential forums. REDUCE-IT attention to Assuming to successful scope reduction mentioned unique product the our here and we the will and the regarding triglyceride study bit timing have targeted. population being an has increased
many you drug. much is may As biological Vascepa recall, effects lowering more has than and triglyceride
the data the is biological suggesting the that endothelia elevated For EPA JELIS ingredient literature and did the benefit in plaque aspects demonstrated in plaque The There in the study product active example, triglyceride group, effect risk EPA the and abroad. which for Vascepa reviewed cell patients XX% in reduction effects have clinical peer improved to rupture. relative atherosclerosis study the treating not levels. of scientific group study, function formation, has on many reported of pathway EPA
separate some in inflammation. measures such LPPLAX. nation significantly demonstrated and of One lower steps the HSCRP two of studies, Phase III the levels Vascepa is In these
not causing reduction number the showed of biomarkers use least pathway mechanism to exact beta events. study of of more is recently the inhibitor role While mase has inflammatory attention. received information of inflammation at a of a atherosclerosis known, that reduction CANTOS a led specific of and one of IL-X a in the The
risk CANTOS can first reduction the pathway evidence inflammatory time the many inhibition provide CANTOS very for study are REDUCE-IT, to the study except other that discussion regarding These studies of between an even lead cholesterol that and also appear FOURIER with data differences study cardiovascular the confirm mase. there no cholesterol, The significant recent study changing low study address cholesterol in community management CTAP but incidence the building changing from to HDL appears the study, events. of residual of cholesterol that While therapy. to or the inhibitor was which levels better the LDL a contributed lower among also impact is levels. cardiovascular triglyceride studies that need residual despite within and to study demonstrated and reducing increased statin another when that LDL A have remains. lipid is of LDL the medical These REVEAL medical all are frontier little next on other biomarkers risk community have to significant the CANTOS is cardiovascular consensus remaining in
of example, such meeting levels as suggesting will more REDUCE-IT results help at CMHC triglyceride study treated. pointed Paul be that create of the should Boston, proactively data anticipate We For a Mike that speak recent SEP in physicians more want to Richter the we Kalb, this Financial and data. consensus Officer prescription many Chief results. this as point, our physicians to see our topic, that realize At financial to on outcomes the and details will
